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stent (BES) versus sirolimus eluting permanent polymer stent (SES) in 81 chronic total
occlusions treated in the all-comers LEADERS trial which included 1,707 patients.
Results: There were no major baseline clinical difference between patient with and
without CTOs, except for slightly higher number of lesions and SYNTAX score in the
CTO group and higher number of patients presenting with STEMI in the non-CTO
group. Overall MACE rate at three years tended to be higher in the CTO group (24.7%
vs 16.6%, HR 1.54; p=0.061). Patients with CTOs treated with BES (n=45) tended to
have lower MACE rate than patients treated with SES (n=36) (15.6% vs 36.1%; HR
0.46; p=0.07) (Table). Mortality rate was 0% in the BES treated group and 11.1% in
the SES treated group. There were no differences in the MI rates but TVR tended to
be lower in the BES treated group (8.9 % vs 19.4%; HR 0.44; p=0.19).
Three year outcomes of chronic total occlusion treatment with biolimus eluting
biodegradable polymer stent versus sirolimus eluting permanent polymer stent
in the LEADERS all-comers trial.
Data presented as N(%). BES: biolimus eluting biodegradable polymer stent; SES:
sirolimus eluting permanent polymer stent; MACE: composite endpoint of cardiac
death, myocardial infarction (MI), and clinically indicated target vessel
revascularization within 9 months.
Conclusion: Three year follow up in patients with CTOs treated in the LEADERS trial
shows that treatment with BES tends to reduce MACE, mortality and TVR rate.
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Background: Successful recanalization of lesions totally occluded for more than 3
months (CTO) remains a challenging and controversial area of interventional
cardiology. We evaluated efficacy and long-term safety after treatment of CTO lesions
with Nobori drug eluting stent (DES), a new generation drug eluting stent coated only
abluminally with a biodegradable polymer and Biolimus A9. Once the polymer is
degraded and the drug completely released, this stent is expected to behave similarly
to BMS.
Methods: A large all comers study is conducted in 125 centers across Europe and Asia.
Primary endpoint of the study is target lesion failure (TLF), a composite of cardiac
death, target vessel related MI and target lesion revascularization (TLR) at 12 months.
Data are entered in an electronic database with extensive on-line and on-site
monitoring. Adverse events are adjudicated by an independent clinical event committee
and a corelab analyzes all angiograms. The pre-specified subgroup with at least one
CTO lesion treated included 98 patients.
Results: CTO patients were 62.1±10.9 years old, 85.6% were males and 63.9%
presented with stable angina; 19.6% had silent ischemia. The number of diseased
vessels and lesions per patient was 1.9±0.8 and 2.2±1.2 respectively. Per patient,
1.5±0.7 highly complex lesions (73% type C) were treated by implantation of 2.0±1.3
study stents in average. QCA pre-procedure for all lesions per patient (including not
occluded) measured RVD of 2.4±0.7mm, MLD 0.3±0.4mm and diameter stenosis
87.7±17.0%. QCA values post-procedure were: RVD 2.9±0.5mm, DS 14.4±6.6% and
acute gain 2.2±0.5mm. At 2 year follow-up, 3 patients died (3.1%), 1 suffered MI
(1.0%) and 3 underwent TLR (3.1%); 90.2% of patients were angina free. MACE
(major adverse cardiac events) and TLF rates were 6.2% and 5.2% respectively and
there were no stent thromboses.
Conclusion: Two year outcomes are proving Nobori stent to be safe and effective when
used to treat totally occluded lesions. Particularly appealing is the absence of stent
thrombosis up to 2 years in spite of multiple overlapping stents.
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Background: The clinical benefit of chronic total occlusions (CTO) recanalisation is
still being discussed.The aim of our study is to analyse long-term clinical results of
CTO recanalisation with drug-eluting stent implantation.
Methods: Patients were divided into groups:main group(A)consisted of patients with
successful revascularization(n-321,mean age 58±9 years)compared with
patients(control group B),who received medical therapy(n-264, mean age 61±10 years).
In the control group revascularization attempt was either unsuccessful(n-57,15.1% of
cases)or was not carried out, so patients in group B were receiving medication at the
same time period. The average follow-up was 1095±36 days. Predictors of survival
without coronary events (angina+myocardial infarction+coronary death)and chronic
heart failure reoccurence were analyzed employing Cox proportional hazards model.
Results: After a period of 3 years of follow-up,the mortality rate and frequency of MI
did not differ between groups.The frequency of angina and chronic heart failure
reoccurence was lower in the group with successful revascularization of
CTO(p<0.05).According to the functional tests, after a period of 3 years of follow-
up,the frequency of positive exercise tolerance tests was higher in group
B(p<0.05).Exercise tolerance was better in group A.Patients in group A required less
antianginal therapy (p<0.05). Analysis of coronary events predictors in both groups
revealed that the main factors negatively affecting the long-term prognosis are: patient’s
age over 65 years and diabetes mellitus (p=0.006).The left anterior descending artery
lesion (p=0.001) is the main factor that increases the risk of heart failure progression
in the long run in group B.3-year survival without coronary events was higher in group
A.Survival without progression of chronic heart failure by the end of the 3d-year of
observation period was also higher in group A.
Conclusion: Revascularization of CTO of coronary arteries is effective and
feasible.Endovascular recanalization of CTO with drug-eluting stent implantation can
improve the long-term prognosis.
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Background: The long-term clinical results after stenting of coronary CTO has not
been fully elucidated.
Methods: Between January 1, 2001 and January 12, 2008, 594 patients with 702 CTO
lesions treated by PCI were studied. The primary endpoint was the occurrence of major
adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI),
and target vessel revascularization (TVR). The secondary endpoints included rates of
perforation and stent thrombosis (ST).
Results: Successful recanalization was achieved in 85.5%. Mean angiographic and
clinical follow-up of 1000.68 days was obtained in 78.6% and 96.7% of cases,
respectively. At 1 year, the increment of MI, cardiac death, TVR, MACE and definite
ST was 1.0%, 0.9%, 3.9%, 5.9% and 0.5%, respectively. The differences in in-hospital
cardiac death, TVR, coronary artery bypass graft (CABG) and MACE between CTO-
PCI success vs. CTO-PCI failure group were sustained throughout the entire follow-up
period. Left ventricular ejection fraction in CTO-PCI success group increased from
50.42±10.01% at baseline to 56.37±6.88% (p=0.037). Incomplete revascularization
was associated with increased cardiac death and/or subsequent CABG. Age>70, lack
of collateral circulation, proximal angulation>450, blunt pattern of occlusion, CTO
length >20mm and proximal severe calcification were predictors of recanalization
failure.
Conclusion: Successful recanalization of CTO was associated with improved clinical
outcomes. Incomplete revascularization was associated with significant increase in
cardiac mortality and/or need for subsequent CABG.
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Background: Chronic total occlusion (CTO) intervention is still challenging because
of the limited procedural success rate and higher target failure. The aim of this study
is to evaluate the impact of lesion length on procedure and clinical outcomes.
Methods: A total 250 consecutive patients (pts) who underwent percutanous coronary
intervention (PCI) with drug-eluting stents (DES) for CTOs were enrolled for this
study. Study population was divided into short lesion group (less than 30 mm, n=123),
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and diffuse long lesion group (more than 30 mm, n=127).
Results: Baseline clinical characteristics & procedure details were similar between the
two groups, except pts with diffuse long lesion were more smokers (59.1% vs. 46.3
%, p: 0.044). In long lesion group; use of retrograde approach, numbers of wires,
microcatheter, amount of dye and total fluoroscopy time, were higher. Except for
perforation, procedure related complications were similar between the two groups. At
one year, diffuse long lesion group showed worse clinical outcomes including higher
incidence of target lesions revascularization (TLR), target vessel revascularization
(TVR) and TLR-major adverse cardiac events (MACE, Table).
Conclusion: Diffuse long CTO lesions needed more complex procedure techniques
and devices. Further, those were associated with worse clinical outcomes at one year
follow up as compared with shorter CTO lesions.
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Background: Stent fracture is related to restenosis after drug-eluting stent (DES)
implantation. As percutaneous coronary intervention (PCI) cases for complex lesions
increase, those for stent fracture-related restenosis could also increase. However, the
optimal PCI strategy for such restenosis remains unclear. We evaluated the results of
PCI with plain old balloon angioplasty (POBA), DES, and drug-eluting balloon (DEB,
SeQuent Please) for restenosis with stent fracture after sirolimus-eluting stent (SES)
implantation.
Methods: From November 2002 to October 2010, 5334 patients with 6299 lesions
underwent SES implantation successfully. Of these lesions, 5298 were angiographically
followed after 6 to 8 months (midterm f/u) and 3981 were followed at 12 months after
midterm f/u (late f/u). Stent fracture occurred at 294 lesions (stent fracture rate, 5.5%)
and stent fracture with restenosis occurred at 123 lesions. Of these 123 lesions, target
lesion revascularization (TLR) by PCI with POBA, DES, or DEB was performed on
80 lesions.
Results: Data are shown in the table. At midterm f/u, the rates of restenosis and TLR
after restenting with DES were significantly lower than those after POBA. At late f/u,
there was no significant difference between POBA and DES. Late f/u was not
performed on the DEB cases.
Conclusion: Restenting with DES could be an acceptable treatment for restenosis with
stent fracture after SES implantation.
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Background: The number of PCI has been increasing during the last years in Europe.
Little is known about the characteristics of interventional treatment of in-stent-re-
stenosis (ISR) in clinical practice in Europe.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were
enrolled into the PCI-Registry of the Euro Heart Survey Programme to document
patient characteristics, PCI details and hospital complications in different PCI
indications. We examined the differences between treatment of ISR versus de novo-
lesions in patients undergoing PCI for ACCS in clinical practice.
Results: A total of 14,011 patients underwent PCI for ACS, in 789 (5.6%) the treated
culprit lesion was an ISR. Patients with ISR more often were male; more often had
diabetes, prior MI and CABG than patients undergoing PCI in de-novo lesions. No
differences were found in the use of anti-thrombotic drugs despite a more frequent use
of GP IIb/IIIa receptor blockers even in patients with de-novo lesions rather than in
ISR. In ISR, 70.1% of patients did receive a stent, of which 64.6% were DES. The rate
of stenting in de-novo lesions was 94.8%, with a relative proportion of 38.0% of DES.
No differences were observed in hospital outcome.
Conclusion: The culprit lesion in consecutive patients undergoing PCI for ACS in
clinical practice in Europe was ISR in 5.6%. Patients with ACS treated for ISR less
often received new stents, of which only two third were DES. No differences were
found in hospital clinical outcome between patients with ISR or de-novo- stenosis in
ACS in clinical practice in Europe.
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Background: As Drug-eluting stents (DES) significantly reduce the risk of in-stent
restenosis (ISR), it has become common practice to perform PCI with DES for
unprotected distal left main (UDLM) stenosis. However, there is little available data
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